المؤلفون: de Velasco G; Department of Medical Oncology, Madrid, Spain. Electronic address: Gdvelasco.gdv@gmail.com., Alonso-Gordoa T; Department of Medical Oncology and Department of Genitourinary, Germ cell and Endocrine Tumors, Ramón y Cajal University Hospital and Ramón y Cajal Health Research Institute (IRYCIS), Madrid, Spain., Rodríguez-Vida A; Department of Medical Oncology, Hospital del Mar-CIBERONC, IMIM Research Institute, Barcelona, Spain., Anguera G; Department of Medical Oncology, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain., Campayo M; Department of Medical Oncology, Hospital Universitari Mutua Terrassa, Terrassa, Barcelona, Spain., Pinto Á; Department of Medical Oncology, University Hospital La Paz, Madrid, Spain., Ortega EM; Department of Medical Oncology, University Hospital of Jaén, Jaén, Spain., Gallardo E; Department of Medical Oncology, University Hospital Parc Taulí, Institut d'Investigació i Innovació Parc Taulí, Sabadell, Spain., Núñez NF; Department of Medical Oncology, University Hospital Lucus Augusti, Lugo, Spain., García-Carbonero I; Department of Medical Oncology, University Hospital of Toledo, Toledo, Spain., Reig O; Department of Medical Oncology, Hospital Clínic and Translational Genomics and Targeted Therapeutics in Solid Tumors Group (IDIBAPS), Barcelona, Spain., Méndez-Vidal MJ; Department of Medical Oncology, University Hospital Reina Sofía, Maimónides Institute for Biomedical research of Córdoba (IMIBIC), Córdoba, Spain., Fernández-Calvo O; Department of Medical Oncology, University Hospital of Ourense, Ourense, Spain., Cassinello NV; Department of Medical Oncology, Hospital Clínico San Carlos, Instituto de Investigación Sanitaria del Hospital Clínico San Carlos (IdISSC), CIBERONC, Madrid, Spain., Torregrosa D; Department of Medical Oncology, University Hospital Dr. Peset, Valencia, Spain., López-Martín A; Medical Oncology Department, University Hospital Severo Ochoa, Madrid, Spain., Rosero A; Department of Medical Oncology, University Hospital Infanta Cristina, Parla, Madrid, Spain., Valiente PG; Department of Medical Oncology, University Hospital Marqués de Valdecilla, Santander, Spain., de España CG; Department of Medical Oncology, University Hospital Son Espases, Palma de Mallorca, Spain., Climent MA; Department of Medical Oncology, Fundación Instituto Valenciano de Oncología, Valencia, Spain., Santasusana MD; Department of Medical Oncology, Hospital Althaia, Manresa, Spain., Sánchez ÁR; Department of Medical Oncology, University Hospital of León, León, Spain., González IC; Department of Medical Oncology, Hospital Clínico Universitario, INCLIVA, University of Valencia, Valencia, Spain., Afonso R; Department of Medical Oncology, University Hospital Nuestra Señora de Candelaria, Santa Cruz de Tenerife, Spain., García Del Muro X; Genitourinary Cancer and Sarcoma Unit, Institut Català d'Oncologia, Hospitalet, Barcelona, Spain., Casinello J; Department of Medical Oncology, University Hospital of Guadalajara, Guadalajara, Spain., Fernández-Parra EM; Department of Medical Oncology, University Hospital Valme, Sevilla, Spain., García Sánchez L; Department of Medical Oncology, University Hospital of Segovia, Segovia, Spain., Afonso J; Department of Medical Oncology, University Hospital of Ferrol, A Coruña, Spain., Polo SH; Department of Medical Oncology, University Hospital Fundación Alcorcón, Madrid, Spain., Asensio Ú; Medical Department, Pfizer Oncology, Madrid, Spain.

المصدر: Clinical genitourinary cancer [Clin Genitourin Cancer] 2023 Jun; Vol. 21 (3), pp. e166-e174. Date of Electronic Publication: 2022 Dec 05.

نوع المنشور: Observational Study; Journal Article; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: Elsevier Country of Publication: United States NLM ID: 101260955 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1938-0682 (Electronic) Linking ISSN: 15587673 NLM ISO Abbreviation: Clin Genitourin Cancer Subsets: MEDLINE

مواضيع طبية MeSH: Carcinoma, Renal Cell*/drug therapy , Carcinoma, Renal Cell*/secondary , Antineoplastic Agents*/therapeutic use , Kidney Neoplasms*/drug therapy , Kidney Neoplasms*/pathology, Humans ; Middle Aged ; Sunitinib/therapeutic use ; Retrospective Studies ; Indoles/therapeutic use ; Pyrroles/therapeutic use